Atazanavir

Drug #1848

Atazanavir is an antiviral agent, active against HIV infection. It belongs to protease inhibitors. Atazanavir is used in combination with other antiretroviral drugs in patients previously treated with antiretroviral.

← Previous drug Next drug →

Primary Characteristics

It belongs to Protease Inhibitor pharmacological group on the basis of mechanism of action.

Molecular Weight: 704.9 · Solubility in Water: 4-5mg/mL · Non-proprietary name: Atazanavir · pH: 1.9.

Pharmacokinetics

Distribution: Atazanavir has a plasma protein binding is 86%.

Elimination: it is metabolised via hepatic, plasma half-life is 7hous.

Indications

Atazanavir is primarily indicated in conditions like HIV infection in combination with other antiretroviral drugs.

Contraindications

Atazanavir is contraindicated in conditions like Diabetes mellitus, Hypersensitivity.

Dosage

Atazanavir's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
300 mg	300 mg	Every 24h	PO	Adults over 18 years, should be taken with 100 mg Ritonavir and food.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown1 interaction

12 interactions

Major1 interaction

Moderate1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Atazanavir is known to cause more or less tolerable side effects which are usually transient. These include Abnormal dreams, Alopecia, Amnesia , Anxiety, Arthralgia, Chest pain, Depression, Diarrhea, Dyspnea, Hypertension , Increased appetite, Jaundice , Mouth ulcers, Nephrolithiasis , Palpitation, Peripheral neuropathy, Proteinuria , Syncope , Urinary frequency, Weight changes.

Warnings / Precautions

Concomitant use with drugs that prolong PR interval; cardiac conduction disorders. Protease inhibitors are associated with hyperglycaemia and should be used with caution in diabetes. Caution is also needed in patients with haemophilia who may be at increased risk of bleeding. Protease inhibitors should be used with caution in hepatic impairment; the risk of hepatic side-effects is increased in patients with chronuc hepatitis B or C. Atazanavir and fosamprenavir may be used at usual doses in patients with renal impairment. Protease inhibitors should also be used with caution in pregnancy.

Available Brands

None recorded.

Storage Conditions

Atazanavir should be stored Drug Form.

Drug Classification

1.6.5.2 — Antiretroviral drugs